GlaxoSmithKline (LON:GSK)‘s stock had its “hold” rating reiterated by Deutsche Bank in a report released on Thursday, September 6th, MarketBeat Ratings reports. They presently have a GBX 1,525 ($19.86) price target on the stock. Deutsche Bank’s target price would indicate a potential upside of 2.75% from the stock’s previous close.

A number of other equities analysts have also issued reports on GSK. UBS Group reissued a “buy” rating and set a GBX 1,600 ($20.84) price target on shares of GlaxoSmithKline in a report on Monday, July 2nd. Citigroup restated a “neutral” rating on shares of GlaxoSmithKline in a research report on Thursday, July 26th. Berenberg Bank restated a “buy” rating and issued a GBX 1,790 ($23.32) price objective (down previously from GBX 1,790 ($23.32)) on shares of GlaxoSmithKline in a research report on Wednesday, August 1st. Goldman Sachs Group set a GBX 1,900 ($24.75) price objective on shares of GlaxoSmithKline and gave the company a “buy” rating in a research report on Friday, June 29th. Finally, Barclays set a GBX 1,750 ($22.80) price target on shares of GlaxoSmithKline and gave the company a “buy” rating in a research report on Tuesday, July 3rd. One investment analyst has rated the stock with a sell rating, thirteen have issued a hold rating and ten have assigned a buy rating to the stock. GlaxoSmithKline has an average rating of “Hold” and an average price target of GBX 1,546.95 ($20.15).

Shares of GSK stock traded down GBX 11.40 ($0.15) during mid-day trading on Thursday, hitting GBX 1,484.20 ($19.33). 8,022,352 shares of the stock were exchanged, compared to its average volume of 9,120,000. GlaxoSmithKline has a 12-month low of GBX 1,235.20 ($16.09) and a 12-month high of GBX 1,724.50 ($22.46).

In other news, insider Philip R. Hampton bought 2,810 shares of the firm’s stock in a transaction on Wednesday, July 25th. The stock was purchased at an average price of GBX 1,557 ($20.28) per share, for a total transaction of £43,751.70 ($56,990.62). Also, insider David Redfern sold 1,925 shares of the company’s stock in a transaction dated Tuesday, July 31st. The stock was sold at an average price of GBX 1,575 ($20.52), for a total transaction of £30,318.75 ($39,492.97). In the last 90 days, insiders bought 2,834 shares of company stock worth $4,412,402.

About GlaxoSmithKline

GlaxoSmithKline plc engages in the creation, discovery, development, manufacture, and marketing of vaccines, over-the-counter medicines, and health-related consumer products worldwide. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, anti-virals, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterials, dermatology, rare diseases, immuno-inflammation, and HIV, as well as vaccines.

Further Reading: Short Selling Stocks, A Beginner’s Guide

Analyst Recommendations for GlaxoSmithKline (LON:GSK)

Receive News & Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related companies with's FREE daily email newsletter.